Cue Biopharma

70 articles with Cue Biopharma

• Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

  6/14/2021

  Cue Biopharma, Inc., a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held June 16-17, 2021.

• Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC

  6/10/2021

  Cue Biopharma, Inc. (Nasdaq: CUE), announced today that it has dosed the first patient in the Part B expansion phase of its Phase 1 monotherapy clinical trial of CUE-101 at the recommended Phase 2 dose of 4mg/kg.

• Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting

  6/3/2021

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will give a presentation at the 2021 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting , which is being held virtually from June 8-11, 2021.

• Cue Biopharma to Present a Corporate and Clinical Progress Update at the Upcoming Jefferies Virtual Healthcare Conference

  5/26/2021

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will present at the Jefferies Virtual Healthcare Conference being held June 1-4, 2021.

• Cue Biopharma Reports First Quarter 2021 Results, Recent Updates of CUE-101 Phase 1 Dose Escalation Study, Platform Progress and Business Highlights

  5/17/2021

  Cue Biopharma, Inc., a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, provided a business and clinical progress update for the first quarter 2021.

• Cue Biopharma to Host Business Update Call and Webcast - May 10, 2021

  5/10/2021

  Cue Biopharma, Inc., a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced it will host a conference call and webcast to provide a business update on Monday, May 17, 2021 at 4:30 p.m. EDT.

• Cue Biopharma Reports Confirmed Partial Response (PR) in Ongoing Phase 1 Monotherapy Study of CUE-101 in Late Stage Second Line and Beyond Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer

  5/10/2021

  Cue Biopharma announced today interim clinical data, including a confirmed partial response (PR), from its ongoing Phase 1a/1b monotherapy study of CUE-101 as second-line treatment for patients with HPV+ R/M HNSCC.

• Cue Biopharma to Present at the 2021 Frontiers in Cancer Immunotherapy Conference

  5/6/2021

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will give a poster presentation at the New York Academy of Sciences 2021 Frontiers in Cancer Immunotherapy meeting,

• Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

  3/16/2021

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, provided a business update for the fourth quarter and full year 2020.

• Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference

  3/15/2021

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will present at the virtual Oppenheimer 31st Annual Healthcare Conference being held March 16-18, 2021.

• Cue Biopharma to Host Business Update Call and Webcast - Mar 09, 2021

  3/9/2021

  Cue Biopharma, Inc., a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced it will host a conference call and webcast to provide a business update on Tuesday, March 16, 2021 at 4:30 p.m. EDT.

• Cue Biopharma to Present at the Cowen 41st Annual Health Care Conference

  3/1/2021

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that it will present at the Cowen 41st Annual Health Care Conference being held virtually from March 1-4, 2021.

• Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Conference

  2/22/2021

  Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma, will deliver an oral presentation and participate in a panel discussion at the 7 th Annual Immuno-Oncology 360° Conference on February 25, 2021

• 

  BioSpace Movers & Shakers, Feb. 19

  2/19/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical Development

  2/17/2021

  Appointment to strengthen clinical development capabilities with a strategic and visionary immunotherapy leader as Cue Biopharma advances its pipeline of drug development programs

• 

  Clinical Catch-Up: February 8-12

  2/15/2021

  It was a busy week for clinical trial announcements and news. Here’s a look.

• Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer

  2/8/2021

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that on February 1, 2021, the first patient was dosed in a Phase 1 dose escalation clinical trial of CUE-101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA

• 

  Advances in the Battle Against Autoimmune Disease

  12/16/2020

  Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. BioSpace has captured some key efforts.

• Cue Biopharma to Present at the Piper Sandler 32nd Annual Healthcare Conference

  11/23/2020

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that it participated in a pre-recorded fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held on December 1-3, 2020. The pre-recorded presentation will be available to

• Cue Biopharma Extends Research Collaboration for the Development of Immuno-STAT Biologics for the Treatment of Defined Autoimmune Diseases with Merck

  11/19/2020

  Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, announced today that the company has extended the term of the research program under its existing 2017 research collaboration and license agreement with Merck toward developing a clinical candidate for the treatment of type 1 diabetes an